Measuring the impact of the Affordable Care Act with Big Data from electronic health records
Claims data from the billing portion of an EHR was used to develop a study cohort of providers who had visits documented prior to January 2011. The study datasets are based on a 29 million ambulatory visits per year (2013 and 2014) across the United States. These visits represent 10 million patient-provider relationships, for 16 thousand providers. We evaluated whether requiring insurance coverage increased utilization for these providers, whether providers saw an increase in new patients, and whether payer mix differed by a state’s status on expanding Medicaid eligibility requirements.
Visits to providers did not change and the proportion of visits from new patients increased only slightly for primary care. As a proportion of all patient visits, visits from Medicaid increased in states that expanded Medicaid, but decreased in states that did not expand Medicaid. In expansion states, visits increased for patients transitioning from uninsured to commercial or Medicaid. In non-expansion states, visits increased only for patients transitioning from uninsured to Medicaid, but not patients transitioning from uninsured to commercial.
Learning Areas:Provision of health care to the public
Public health or related laws, regulations, standards, or guidelines
Public health or related public policy
Demonstrate the utility of a novel data source for health policy research
Keyword(s): Affordable Care Act, Data Collection and Surveillance
Qualified on the content I am responsible for because: I am a statistician who uses electronic health records data for public policy research. My current role includes project director for joint research with the Robert Wood Johnson Foundation to measure the evaluate the impact of the Affordable Care Act
Any relevant financial relationships? Yes
|Name of Organization||Clinical/Research Area||Type of relationship|
|athenahealth||Electronic Health Records||Employment (includes retainer)|
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.